The company is involved in ongoing patent litigation with Teva Pharmaceuticals concerning its drug Korlym. A favorable outcome would protect its market exclusivity until 2037. Analysts from Wolfe Research have initiated coverage with a 'Peer Perform' rating, suggesting the stock will likely trade in the $70 to $75 range until there is a resolution from a future earnings call. The company has also modified its revenue guidance and is banking on its Cushing Syndrome treatment to drive future growth.